Get the Stockscreener App
27.58
3.84%
1.02
After Hours:
27.58
Aktis Oncology Inc Stock (AKTS) Forecast
The Aktis Oncology Inc (AKTS) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $4.6226, representing a -83.24% decrease from the current price of $27.58. The highest analyst price target is $5.8307, and the lowest is $3.4144.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month AKTS Price Target
Average 3.8139
(-86.17% Downside)
Is Aktis Oncology Inc (AKTS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 56.75 | Neutral |
| STOCH(9,6) | 57.81 | Neutral |
| STOCHRSI(14) | 10.77 | Buy |
| MACD(12,26) | 2.5366 | Buy |
| ADX(14) | 36.55 | Buy |
| William %R | -48.14 | Neutral |
| CCI(14) | -2.1368 | Neutral |
Buy: 3
Sell: 0
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
29.57
Sell
|
28.42
Sell
|
| MA20 |
25.47
Buy
|
26.43
Buy
|
| MA50 |
21.88
Buy
|
23.23
Buy
|
| MA100 |
20.27
Buy
|
21.49
Buy
|
| MA200 |
12.39
Buy
|
0.00
Buy
|
Buy: 8
Sell: 2
Neutral: 0
Summary: Buy
According to our latest analysis, AKTS could be considered a Strong Buy, with 17 technical analysis indicators signaling 11 Buy signals, 2 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on AKTS, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 56.75 indicates that AKTS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 57.81 indicates that AKTS is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 10.77 indicates that AKTS is oversold. This suggests that AKTS price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 36.55 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -2.1368 indicates that AKTS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term AKTS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Aktis Oncology Inc financial reports and earnings history, Aktis Oncology Inc (AKTS) stock could reach $7.79 by 2030, $3.1547 by 2040 and $11.92 by 2050. See the projected annual prices until 2050 of the Aktis Oncology Inc stock below:
- Aktis Oncology Inc (AKTS) is expected to reach an average price of $1.8209 in 2035, with a high prediction of $2.0921 and a low estimate of $1.8639. This indicates an $-93.40% rise from the last recorded price of $27.58.
- Aktis Oncology Inc (AKTS) stock is projected to chart a bullish course in 2040, with an average price target of $3.2359, representing an $-88.27% surge from its current level. The forecast ranges from a conservative $2.9672 to a sky-high $3.1547.
- Our analysts predict Aktis Oncology Inc (AKTS) to jump -69.47% by 2045, soaring from $8.0054 to an average price of $8.4203, potentially reaching $8.1704. While $8.0054 is the low estimate, the potential upside is significant.
- Aktis Oncology Inc (AKTS) stock is expected to climb by 2050, reaching an average of $11.66, a $-57.71% jump from its current level. However, a wide range of estimates exists, with high and low targets of $11.92 and $12.21, respectively, highlighting the market's uncertainty.
Aktis Oncology Inc Stock (AKTS) Year by Year Forecast
Aktis Oncology Inc Stock (AKTS) Price Forecast for 2026
The predicted value for Aktis Oncology Inc (AKTS) in 2026 is set at an average of $8.0087. Estimates vary from a peak of $14.01 to a trough of $2.008, indicating an -70.96% surge from the present price of $27.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| August, 2026 | $5.4307 | $3.4144 | $5.8307 | -80.31% |
| September, 2026 | $5.4395 | $4.7995 | $6.8582 | -80.28% |
| October, 2026 | $5.0945 | $4.097 | $5.6932 | -81.53% |
| November, 2026 | $5.5395 | $3.272 | $5.8358 | -79.91% |
| December, 2026 | $5.4483 | $4.7946 | $6.4883 | -80.25% |
Aktis Oncology Inc Stock (AKTS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Aktis Oncology Inc (AKTS) is $2.7936, with a high forecast of $5.5774 and a low forecast of $0.00981. This indicates an -89.87% decrease from the last price of $27.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.0233 | $2.9733 | $5.5774 | -89.04% |
| February, 2027 | $2.8884 | $2.8384 | $4.4716 | -89.53% |
| March, 2027 | $2.8971 | $1.9036 | $3.6671 | -89.50% |
| April, 2027 | $2.0322 | $1.8422 | $3.4946 | -92.63% |
| May, 2027 | $1.6472 | $0.7697 | $2.4572 | -94.03% |
| June, 2027 | $2.186 | $1.4085 | $2.7622 | -92.07% |
| July, 2027 | $2.951 | $1.5535 | $3.451 | -89.30% |
| August, 2027 | $1.296 | $1.261 | $3.6285 | -95.30% |
| September, 2027 | $0.9148 | $0.0852 | $1.5881 | -96.68% |
| October, 2027 | $0.2798 | $0.00981 | $1.3961 | -98.99% |
| November, 2027 | $0.5248 | $0.2833 | $1.1273 | -98.10% |
| December, 2027 | $2.2036 | $0.2136 | $2.2136 | -92.01% |
Aktis Oncology Inc Stock (AKTS) Price Forecast for 2028
In 2028, Aktis Oncology Inc (AKTS) is projected to reach an average price of $1.3319, with a high projection of $2.6413 and a low estimate of $0.0226. This indicates an -95.17% fall from the last price of $27.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.1686 | $1.1486 | $2.2374 | -95.76% |
| February, 2028 | $0.1337 | $0.0663 | $1.5524 | -99.52% |
| March, 2028 | $0.6124 | $0.0226 | $0.6624 | -97.78% |
| April, 2028 | $1.0175 | $0.3362 | $1.3337 | -96.31% |
| May, 2028 | $0.0238 | $0.0638 | $1.385 | -99.91% |
| June, 2028 | $0.6113 | $0.13 | $1.3513 | -97.78% |
| July, 2028 | $2.0163 | $0.68 | $2.6413 | -92.69% |
| August, 2028 | $0.9951 | $0.935 | $2.03 | -96.39% |
| September, 2028 | $0.9801 | $0.5063 | $1.3088 | -96.45% |
| October, 2028 | $0.8951 | $0.6151 | $1.4268 | -96.75% |
| November, 2028 | $1.4239 | $0.6439 | $1.4339 | -94.84% |
| December, 2028 | $1.3889 | $1.0425 | $1.7077 | -94.96% |
Aktis Oncology Inc Stock (AKTS) Price Forecast for 2029
The 2029 price forecast for Aktis Oncology Inc Stock (AKTS) is $3.3898 on average, with a high prediction of $6.76 and a low estimate of $0.0195. This represents an -87.71% decrease from the previous price of $27.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.7177 | $0.5989 | $1.4727 | -97.40% |
| February, 2029 | $0.1927 | $0.1477 | $0.7407 | -99.30% |
| March, 2029 | $0.6364 | $0.0535 | $0.2399 | -97.69% |
| April, 2029 | $0.6373 | $0.6572 | $0.6078 | -97.69% |
| May, 2029 | $0.7084 | $0.7385 | $0.7762 | -97.43% |
| June, 2029 | $0.6044 | $0.6233 | $0.5736 | -97.81% |
| July, 2029 | $0.2444 | $0.2651 | $0.5397 | -99.11% |
| August, 2029 | $0.3861 | $0.3395 | $0.3258 | -98.60% |
| September, 2029 | $0.2169 | $0.2246 | $0.2809 | -99.21% |
| October, 2029 | $0.1773 | $0.2111 | $0.1738 | -99.36% |
| November, 2029 | $0.1638 | $0.1146 | $0.1038 | -99.41% |
| December, 2029 | $6.94 | $0.0195 | $6.76 | -74.84% |
Aktis Oncology Inc Stock (AKTS) Price Forecast for 2030
Aktis Oncology Inc Stock (AKTS) is expected to reach an average price of $6.6472 in 2030, with a high forecast of $8.7148 and a low forecast of $4.5795. This signifies an -75.90% decrease from the last price of $27.58.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $7.8824 | $7.6825 | $7.79 | -71.42% |
| February, 2030 | $8.8974 | $8.4449 | $8.1474 | -67.74% |
| March, 2030 | $8.8423 | $8.9823 | $8.6249 | -67.94% |
| April, 2030 | $6.9623 | $8.0773 | $8.7148 | -74.76% |
| May, 2030 | $6.2847 | $6.4547 | $6.1247 | -77.21% |
| June, 2030 | $5.4347 | $5.8447 | $5.9372 | -80.29% |
| July, 2030 | $6.2121 | $5.5897 | $5.9346 | -77.48% |
| August, 2030 | $5.4571 | $5.5271 | $5.5596 | -80.21% |
| September, 2030 | $4.497 | $5.179 | $5.2321 | -83.69% |
| October, 2030 | $5.1995 | $4.5795 | $5.295 | -81.15% |
| November, 2030 | $8.3694 | $5.352 | $6.8894 | -69.65% |
| December, 2030 | $8.3094 | $7.4869 | $7.6125 | -69.87% |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):